Wes Streeting: Weight-loss jabs are the ‘talk of the House of Commons tea rooms'
Currently, the National Health Service (NHS) offers these prescriptions through specialist weight-management services. Eligibility is restricted to individuals with a body mass index (BMI) of 35 or more, or those with a BMI of 30 who also have a linked health condition.
Other people are paying hundreds of pounds a month to get the jabs privately.
Mr Streeting told LBC radio: 'Weight-loss jabs are the talk of the House of Commons, half my colleagues are on them and are judging the rest of us saying 'you lot should be on them'.
'And the thing is, if you can afford these weight loss jabs, which can be over 200 quid a month, well that's all right for you.
'But most people in this country haven't got spared two and a half grand a year and often the people who have the worst and most challenging obesity also have the lowest income.
'So I'm bringing to weight loss jabs the principle of fairness which has underpinned the NHS.
'It should be available based on need and not the ability to pay.
'And that's what we're going to do on weight loss jabs, as well as a number of other things, including people getting more fit, more active, supporting people on diet and nutrition….that's the bit of the weight loss jab debate that sometimes gets lost.
'It's not that you can have some weight loss jabs and stuff your face with Jaffa cakes…'
He said obesity cost the NHS billions a year, adding that taxes have been going 'up and up' to pay for the health service.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
37 minutes ago
- Medscape
Ileal Resection Tied to Higher CRC Risk in Crohn's Disease
TOPLINE: Patients with Crohn's disease who undergo terminal ileum resection have a significantly higher risk of developing colorectal cancer (CRC) and colorectal polyps than those who do not undergo resection. METHODOLOGY: Up to 70% of patients with Crohn's disease undergo ileocecal resection, which increases colonic bile acid flux exposure and potentially promotes induction of tumorigenic pathways. However, the direct impact of terminal ileum resection on CRC risk in Crohn's disease remains uncertain. Researchers conducted a retrospective cohort study (2005-2024) using U.S. electronic health record data from adults with Crohn's disease to assess the association between terminal ileum resection and CRC risk. The primary outcome was the risk for CRC in patients with and without terminal ileum resection. Secondary outcomes included the risk for CRC based on biologics use and colonic involvement, and risk for benign colonic polyps. TAKEAWAY: Researchers included 13,617 patients with Crohn's disease who underwent terminal ileum resection (mean age, 39.5 years; 51.3% female) and an equal number of matched controls without resection. Terminal ileum resection was associated with a significantly higher risk for CRC (adjusted hazard ratio [aHR], 2.58; P < .001), which was consistent in both men (aHR, 4.23; P < .001) and women (aHR, 2.43; P < .01). Elevated CRC risk persisted regardless of colonic involvement (P < .01). CRC risk did not significantly differ between patients who received biologic therapy and those who were biologic naive. Patients with resection also had a higher risk for nonmalignant colonic polyps (aHR, 1.11; P < .01), which was consistent in both men and women (P < .01 for both). IN PRACTICE: "Our findings highlight the need to reassess CRC surveillance strategies in patients with [Crohn's disease] post-[terminal ileum] resection. While current guidelines focus on inflammation-related risk, our results suggest that surgical history itself is an independent risk factor," the authors concluded. SOURCE: This study was led by Inas Mikhail, MD, Mayo Clinic, Jacksonville, Florida, and Omar Al Ta'ani, MD, Allegheny Health Network, Pittsburgh, Pennsylvania. It was published online in Inflammatory Bowel Diseases. LIMITATIONS: The retrospective design may introduce biases related to reporting, selection, and follow-up. Residual confounding factors may have persisted despite propensity score matching. Due to a lack of data on bile acid profile and inflammatory burden, it could not be determined whether dysregulation of bile acids was directly involved in CRC risk. DISCLOSURES: This study authors reported no specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Semaglutide Has Found Its STRIDE
Key results and new insights from the STRIDE trial and the evolving role of GLP-1 receptor agonist (RA) therapy in type 2 diabetes (T2D) and peripheral arterial disease (PAD) were discussed during a symposium at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, which I was fortunate to attend. A Common Comorbidity T2D and PAD are not strangers to one another; patients with T2D are twice as likely to develop PAD compared with the general population. PAD has been shown to be the most common initial manifestation of cardiovascular disease in T2D. Moreover, patients with diabetes foot complications fear amputation and infection more than death. However, PAD is underrecognized in T2D; only around 20% of patients present with the classical symptoms of intermittent claudication (IC). PAD also has insidious onset: Patients experience slow functional decline and leg discomfort, which is often not recognized as PAD by healthcare professionals or patients. T2D and PAD are growing in incidence and share many risk factors, including obesity. A recent systematic literature review exploring the epidemiology and burden of PAD in T2D found that 12.5%-22% of patients with T2D had comorbid PAD. Furthermore, patients with T2D and PAD have a very high risk for major lower-limb complications and major adverse cardiovascular events, including all-cause and cardiovascular mortality. Unsurprisingly, PAD was associated with poor quality of life and significant healthcare use and costs. Notably, the ADA 2025 Standards of Medical Care in Diabetes now recommends screening for PAD using ankle-brachial index (ABI) testing in asymptomatic patients with diabetes aged > 65 years, microvascular disease in any location, or foot complications or any end-organ damage from diabetes if a PAD diagnosis would change management. PAD screening should also be considered in patients with diabetes duration > 10 years and high cardiovascular risk. PAD in T2D is often recalcitrant to surgical intervention because it tends to affect the distal vasculature (that is, the infrapopliteal vessels). These lesions are less amenable to traditional revascularization procedures such as femoropopliteal bypass and stenting. Unfortunately, this circumstance often leaves patients with T2D and PAD with persistent debilitating symptoms and few surgical options. Many international medical guidelines have class I recommendations to consider SGLT2 inhibitors and GLP-1 RAs for patients with T2D and atherosclerotic cardiovascular disease, though not specifically PAD. The only class I recommendation in PAD is for cilostazol for improving claudication symptoms. Cilostazol is a phosphodiesterase 3 inhibitor that promotes vasodilation and increased blood flow, which can improve symptoms of IC (but not cardiovascular outcomes). A recent Cochrane review found that cilostazol resulted in only a 40 m improvement in absolute claudication distance. From my clinical experience, cilostazol is often poorly tolerated (headache and diarrhea are common). It is contraindicated in heart failure, which frequently occurs with PAD. STRIDE Results The randomized controlled STRIDE trial was published in the Lancet in May 2025 and explored the impact of subcutaneous semaglutide (1 mg weekly) plus standard of care, compared with placebo, on walking capacity in patients with symptomatic PAD and T2D. In essence, STRIDE has laid the foundation for a paradigm shift in how we use GLP-1 RAs for symptomatic PAD. The trial recruited 792 patients with T2D and Fontaine stage IIa PAD. Fontaine stage IIa is early-stage symptomatic PAD, in which patients experience symptoms of IC after walking more than 200 m. Mean ABI was ≤ 0.9 in all participants; a normal ABI is typically 0.90-1.30 and indicates normal blood flow to the lower limbs. One-quarter of participants were female, and median age was 68 years. Obesity was not a criterion for study enrollment; 35% of participants had a BMI < 27. The primary outcome of the study was maximum walking distance after 52 weeks compared with baseline. STRIDE achieved its primary outcome. Subcutaneous semaglutide was associated with a significantly increased maximum walking distance (40 m improvement on a 12% incline, which is equivalent to 80 m improvement on a flat surface). This improvement is double that associated with cilostazol and, importantly, was confirmed to be clinically meaningful. The researchers also observed significantly improved symptoms and quality of life, as evidenced by improvements in the VascuQoL questionnaire. Notably, the reported improvements in ABI and disease progression confirm the vascular benefits of semaglutide. Encouragingly, clinical benefits persisted even 5 weeks after stopping semaglutide therapy. The treatment's safety profile was consistent with previous semaglutide trials, and no unexpected safety findings emerged. New data presented and simultaneously published in Diabetes Care confirmed that the effect of semaglutide on maximum walking distance was consistent, irrespective of T2D characteristics; benefits were independent of baseline diabetes duration, BMI, HbA1c, or concomitant use of sodium/glucose cotransporter 2 inhibitors or insulin. Functional benefits did not appear to correlate with weight loss or glycemic improvement, again highlighting the vascular benefits of semaglutide in reducing atherosclerosis, possibly through an anti-inflammatory effect. In conclusion, STRIDE increases the suite of recognized cardiometabolic and renal benefits of semaglutide by adding improved walking capacity, quality of life, and disease progression for patients with T2D and PAD. During my resident year as a junior doctor, my vascular consultant always reminded me of the core management of PAD in five words: 'stop smoking and keep walking.' While this remains the cornerstone of management 25 years later, semaglutide is now well positioned as a foundational therapy to improve quality and quantity of life in patients with T2D and PAD.
Medscape
an hour ago
- Medscape
Brain Changes Linked to Dementia Found in Ex-Rugby Players
Two studies led by researchers at Imperial College London (ICL) have identified structural brain changes and blood biomarkers linked to dementia in former professional rugby players. The findings provide the first prospective evidence of physical brain and blood abnormalities in this group. Previous research had already shown that elite rugby players face a higher risk of neurodegenerative diseases later in life. The studies examined links between repeated head impacts in rugby and conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Post-mortem examinations of former players have shown neuropathologies consistent with repetitive brain trauma. Traumatic brain injury, already a known risk factor for neurodegeneration, contributes to an estimated 3%-15% of dementia cases in the general population. While recent advances in fluid and imaging biomarkers have transformed dementia diagnosis, these techniques have not been systematically applied to rugby players previously exposed to multiple head impacts. Study Cohort and Methods The research involved 200 ex-professional rugby players aged 30-61 (median age, 44), all of whom had self-referred with brain health concerns but had no dementia diagnosis at baseline. At least one previous concussion while playing was reported by 193 (96.5%) of the former players, with a median of seven concussions. The rugby group was compared with 33 age- and sex-matched healthy controls with no evidence of previous head trauma or dementia onset. Participants were 90% male. The median rugby career lasted 10.5 years, with 63% playing as forwards and 37% as backs. Mental Health and Behavioural Symptoms The former players scored higher on self-rated scales of depression, anxiety, and post-concussion symptoms than those in the control group, though not on sleep quality. These symptoms, along with behaviour ratings of executive dysfunction and neuropsychiatric symptom severity, were more prevalent among individuals who had experienced a greater number of self-reported concussions. However, this was unrelated to the number of years played, or position of play. Despite frequent subjective memory complaints, the performance of players in cognitive testing did not differ significantly from that of the control group. However, 24 former players, particularly those who had played as forwards and those who had reported more concussions, met the research criteria for CTE syndrome based on neurobehavioural disturbance. This was determined with low provisional levels of certainty: 21 were classed as 'suggestive.' three as 'possible.' and none as 'probable/definite.' Seven of the 24 had cognitive impairment, 12 had neurobehavioral dysregulation, and five had both. Imaging Findings 3T MRI imaging showed the presence of cavum septum pellucidum in 24% of players, compared with 12% of controls. This was more common in those who had experienced more concussions. They also showed reduced volumes in the frontal and cingulate cortices, with reduced white matter and lower hippocampal volume associated with longer career durations. Only 4.6% showed trauma-associated white matter changes on diffusion tensor imaging. Elevated Blood Biomarkers Using ultrasensitive digital enzyme-linked immunosorbent assays, researchers analysed fluid biomarkers associated with neurodegeneration. Key findings included: Phospho-tau217 levels were 17.6% higher in former players 23.1% had elevated phospho-tau217 9.0% had raised plasma neurofilament light While levels were lower than in late-onset Alzheimer's patients, players with elevated markers had more severe neuropsychiatric symptoms, including depression and anxiety. Frontal brain volumes correlated negatively with neurofilament light, and hippocampal volumes correlated negatively with phospho-tau217. The findings were published simultaneously in two papers in the journal Brain . Professor David Sharp, director of the UK Dementia Research Institute Centre for Care Research & Technology at ICL, who co-led the work, said: 'We didn't see any cases of early dementia in this group of former players, which is reassuring. However, the changes in blood biomarkers and brain imaging abnormalities show some long-term effects of repeated head impacts on the brain.' The studies are set to continue for a further 4 years. Calls for Action on Player Safety 'Nearly half of dementia cases are linked to known health and lifestyle risk factors, including traumatic brain injury from contact sports like rugby,' said Dr Jacqui Hanley, head of research at Alzheimer's Research UK. While not much is known about how such injuries cause changes to the brain, 'deepening our understanding could ultimately help lower dementia risk for professional sportspeople.' Hanley called for stronger efforts to reduce head injury in contact sports, stating: 'Reducing traumatic brain injury in contact sports is critical to help prevent brain damage and minimise dementia risk for the players.' The Alzheimer's Society echoed the concern, noting that professional rugby players face approximately twice the risk of dementia. They called for accurate data on injury patterns and their long-term effects. However, they also stressed that physical activity remains one of the most effective ways to reduce dementia risk. The Dementia Trust has warned that repeated tackles, scrums, and collisions can contribute to CTE among rugby players and noted a rise in early-onset dementia among retired professional players. In 2023, a group of 260 former professionals launched a lawsuit against World Rugby, the Welsh Rugby Union, and the Rugby Football Union. They alleged negligence in failing to protect players from the risk of neurodegenerative diseases.
